Molecular and cellular basis of epidermodysplasia verruciformis

疣状表皮发育不良的分子和细胞基础

基本信息

  • 批准号:
    9887337
  • 负责人:
  • 金额:
    $ 42.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-02-10 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

Project Summary Epidermodysplasia verruciformis (EV) was the first described primary immunodeficiency (PID). By 1946, it was shown by Lutz to be an autosomal recessive (AR) predisposition to skin-tropic viruses, prior to the description of congenital neutropenia by Kostmann (1950). Its lack of associated immunological phenotypes long prevented its recognition as a PID. EV is characterized by disseminated and persistent flat warts, which often evolve into skin cancer. The lesions are caused by E5- and E8-deficient members of the β genus of human papillomaviruses (HPVs), which exclusively reside in keratinocytes and remain silent in the general population. EV typically strikes otherwise healthy individuals (“isolated EV”), or rarely occurs in the context of other infectious diseases (“syndromic EV”). In 2002, bi-allelic mutations in TMC6 and TMC8, encoding EVER1 and EVER2, were found in patients with isolated EV, whose T cells were normal. Bi-allelic mutations in CIB1 were reported in 2018 in other patients with isolated EV. Remarkably, CIB1, EVER1, and EVER2 form a complex that binds to E5 and E8. This complex operates as a restriction factor governing keratinocyte-intrinsic immunity to β-HPVs. From 2012 onward, mutations in RHOH, STK4, and other T cell genes were found in patients with syndromic EV. We hypothesize that other, related single-gene inborn errors of cutaneous immunity against β-HPVs, underlie EV in other patients. The goal of this application is thus to analyze in greater depth the molecular and cellular basis of isolated and syndromic EV. First, we will discover new genetic etiologies of EV thanks to the ongoing recruitment of unrelated EV families, by combining genome-wide linkage (GWL) and whole exome sequencing (WES). Second, we will functionally characterize the novel genotypes by studying the mutant proteins in isolation and in the patients’ cells, including their relationship with the products of the known EV-causing genes, such as the EVER-CIB1 complex in keratinocytes and RhoH or STK4 in T cells. Third, we will model HPV infection of keratinocytes in the presence of T cells in vitro, with viral proteins and particles, using keratinocyte cell lines, foreskin keratinocytes, the patients’ keratinocytes, or induced pluripotent step cell (iPSC)-derived keratinocytes, which will be edited by CRISPR/Cas9. Our project is highly innovative yet supported by strong preliminary data. Indeed, we have recruited 52 novel families, identified three novel genetic etiologies, underlying isolated (mutations in RBPJ) or syndromic EV (ITGAL and OX40), and began elucidating their mechanistic connection with keratinocytes and T cells, respectively. Our research provides novel insights into the mechanisms of cutaneous immunity to β-HPVs, highlighting the dual contribution of keratinocyte-intrinsic immunity and T-cell adaptive immunity. Our research benefits EV patients and families, with the development of novel diagnostic approaches, including genetic counseling, and facilitating the development of novel therapeutic approaches based on a rational understanding of the pathogenesis. Finally, the study of EV is a fruitful model to analyze other mucosal and cutaneous illnesses caused by other HPVs.
项目摘要 疣状表皮发育不良(EV)是最早发现的原发性免疫缺陷(PID)。到1946年, Lutz显示,在描述皮肤嗜性病毒之前, 先天性中性粒细胞减少症,Kostmann(1950)。由于缺乏相关的免疫表型, 识别为PID。EV的特征是播散性和持续性扁平疣,通常演变为皮肤 癌病变是由人乳头瘤病毒β属E5和E8缺陷成员引起的 HPV(人类乳头状瘤病毒),其仅存在于角质形成细胞中并且在一般人群中保持沉默。电动汽车通常罢工 其他健康个体(“孤立EV”),或很少在其他传染病背景下发生 (“综合征EV”)。2002年,在TMC 6和TMC 8中发现了编码EVER 1和EVER 2的双等位基因突变, 分离EV患者,其T细胞正常。2018年在其他研究中报告了CIB 1的双等位基因突变 孤立性EV患者。值得注意的是,CIB 1,EVER 1和EVER 2形成了一个与E5和E8结合的复合物。这 复合物作为控制角化细胞对β-HPV的内在免疫的限制因子起作用。从2012年开始, 在EV综合征患者中发现了RHOH、STK 4和其他T细胞基因的突变。我们假设 其他相关的单基因先天性皮肤抗β-HPV免疫缺陷是其他患者EV的基础。 因此,本应用程序的目标是更深入地分析分离的和 EV综合征首先,我们将发现新的EV遗传病因,这要归功于正在招募的无关的 EV家族,通过结合全基因组连锁(GWL)和全外显子组测序(WES)。二是 通过研究分离的突变蛋白和患者的突变蛋白, 细胞,包括它们与已知EV致病基因产物的关系,如EVER-CIB 1 复合物和T细胞中的RhoH或STK 4。第三,我们将对HPV感染的角质形成细胞进行建模, 使用角质形成细胞系,包皮角质形成细胞, 患者的角质形成细胞或诱导多能性步进细胞(iPSC)衍生的角质形成细胞,其将由 CRISPR/Cas9.我们的项目具有高度创新性,但有强大的初步数据支持。我确已 招募了52个新的家庭,确定了三种新的遗传病因,潜在的孤立(RBPJ突变)或 综合征型EV(ITGAL和OX 40),并开始阐明其与角质形成细胞和T 单元格。我们的研究为β-HPV的皮肤免疫机制提供了新的见解, 突出了角质形成细胞内在免疫和T细胞适应性免疫的双重作用。我们的研究 随着新诊断方法的发展,包括遗传学, 咨询,并促进基于理性理解的新型治疗方法的发展 的发病机制。最后,EV的研究是分析其他粘膜和皮肤疾病的富有成效的模型 其他HPV引起的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jean-Laurent Casanova其他文献

Jean-Laurent Casanova的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jean-Laurent Casanova', 18)}}的其他基金

Human Genetics of Tuberculosis
结核病的人类遗传学
  • 批准号:
    10430226
  • 财政年份:
    2021
  • 资助金额:
    $ 42.43万
  • 项目类别:
Human Genetics of Tuberculosis
结核病的人类遗传学
  • 批准号:
    10268806
  • 财政年份:
    2021
  • 资助金额:
    $ 42.43万
  • 项目类别:
Inborn errors of immunity in patients with life-threatening COVID-19
危及生命的 COVID-19 患者先天性免疫缺陷
  • 批准号:
    10655372
  • 财政年份:
    2021
  • 资助金额:
    $ 42.43万
  • 项目类别:
Inborn errors of immunity in patients with life-threatening COVID-19
危及生命的 COVID-19 患者先天性免疫缺陷
  • 批准号:
    10278180
  • 财政年份:
    2021
  • 资助金额:
    $ 42.43万
  • 项目类别:
Inborn errors of immunity in patients with life-threatening COVID-19
危及生命的 COVID-19 患者先天性免疫缺陷
  • 批准号:
    10449276
  • 财政年份:
    2021
  • 资助金额:
    $ 42.43万
  • 项目类别:
Human Genetics of Tuberculosis
结核病的人类遗传学
  • 批准号:
    10621305
  • 财政年份:
    2021
  • 资助金额:
    $ 42.43万
  • 项目类别:
Molecular and cellular basis of epidermodysplasia verruciformis
疣状表皮发育不良的分子和细胞基础
  • 批准号:
    10561607
  • 财政年份:
    2020
  • 资助金额:
    $ 42.43万
  • 项目类别:
Monogenic basis of resistance to SARS-CoV2 and predisposition to severe COVID-19
抗 SARS-CoV2 的单基因基础和严重 COVID-19 的易感性
  • 批准号:
    10159675
  • 财政年份:
    2020
  • 资助金额:
    $ 42.43万
  • 项目类别:
Molecular and cellular basis of epidermodysplasia verruciformis
疣状表皮发育不良的分子和细胞基础
  • 批准号:
    10352425
  • 财政年份:
    2020
  • 资助金额:
    $ 42.43万
  • 项目类别:
Inherited IRF9 deficiency: a novel genetic etiology of severe influenza
遗传性 IRF9 缺陷:严重流感的新遗传病因
  • 批准号:
    9510816
  • 财政年份:
    2018
  • 资助金额:
    $ 42.43万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 42.43万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 42.43万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 42.43万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 42.43万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 42.43万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 42.43万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 42.43万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 42.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 42.43万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 42.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了